Profil
Amanda Cray currently works as Senior Director-IR & Corporate Communications at Fusion Pharmaceuticals, Inc. and as Head-Investor Relations at Autolus Therapeutics Plc since 2024.
Former roles include Associate Director-IR & Corporate Communications at Aegerion Pharmaceuticals, Inc. from 2012 to 2019, Director-IR & Corporate Communications at Novelion Therapeutics, Inc. from 2016 to 2019, Senior Account Executive at LaVoie Strategic Communications Group, Inc., Associate at Sharon Merrill Associates, Inc., and Account Manager at Harron & Associates, Inc. Education includes graduate studies at Boston University and undergraduate studies at the University of New Hampshire.
Postes actifs de Amanda Cray
| Sociétés | Poste | Début |
|---|---|---|
| FUSN PHAR | Investor Relations Contact | - |
| AUTOLUS THERAPEUTICS PLC | Investor Relations Contact | 01/11/2024 |
Anciens postes connus de Amanda Cray
| Sociétés | Poste | Fin |
|---|---|---|
| AEGERION PHARMACEUTICALS, INC. | Investor Relations Contact | 01/07/2019 |
| NOVELION THERAPEUTICS INC. | Investor Relations Contact | 01/07/2019 |
Sharon Merrill Associates, Inc.
Sharon Merrill Associates, Inc. Miscellaneous Commercial ServicesCommercial Services Provides strategic advisory services | Corporate Officer/Principal | - |
Harron & Associates, Inc. | Corporate Officer/Principal | - |
LaVoie Strategic Communications Group, Inc.
LaVoie Strategic Communications Group, Inc. Advertising/Marketing ServicesCommercial Services Provides strategic communications programs, strategy and brand positioning services | Corporate Officer/Principal | - |
Formation de Amanda Cray
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases | Health Technology |
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of New Hampshire
University of New Hampshire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LaVoie Strategic Communications Group, Inc.
LaVoie Strategic Communications Group, Inc. Advertising/Marketing ServicesCommercial Services Provides strategic communications programs, strategy and brand positioning services | Commercial Services |
Sharon Merrill Associates, Inc.
Sharon Merrill Associates, Inc. Miscellaneous Commercial ServicesCommercial Services Provides strategic advisory services | Commercial Services |
Harron & Associates, Inc. | |
Novelion Therapeutics, Inc.
Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals for the treatment of cancer | Health Technology |
Autolus Therapeutics Plc
Autolus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of gene therapies | Health Technology |
















